FDA approves wearable device Embrace for seizure detection
Category: #health  By Saipriya Iyer  Date: 2018-02-07
  • share
  • Twitter
  • Facebook
  • LinkedIn

FDA approves wearable device Embrace for seizure detection

Empatica Incorporation, reputed for developing wearable medical sensors based on human data analytics, has reportedly received the FDA approval for its award-winning smart watch. Embrace, as the device is popularly called, deploys AI technology for monitoring ‘generalized tonic-clonic’ & grand mal seizures and then sends alerts to caretakers for help.

As per Managed Care, a clinical study had been carried out on nearly 135 epileptics in the level 4 epilepsy monitoring units for more than 272 days. Apparently, the patients were subject to constant monitoring through video-EEG while wearing the smart watch. Post the study, Embrace was deemed successful in detecting nearly 100% of the seizures in the patients.

Healthcare service providers claim that Embrace indeed has the ability to measure myriad symptoms of seizures, having deployed electrodermal activity to detect the same. Reportedly, the smart watch has already received a green signal from the European authorities with the government approving its use as a medical equipment for seizure detection in early 2017.

As per the CDC, nearly 3.4 million of the U.S. populace, including more than 450,000 children, are affected by epilepsy. The National Public Health Institute states that approximately 35% of the epileptics fail to respond to the medication for controlling seizures while around one-third of the patients suffering from epilepsy have a partial response. Post Embrace’s launch, it has been speculated that wearable products such as smart watches can help patients receive timely treatment for epilepsy through early detection of seizures.

The Director of the Comprehensive Epilepsy Center at the New York University has declared that the decision by FDA to approve Embrace is a major landmark across the U.S. healthcare sector. He further states that the U.S. is likely to be majorly benefited through the product launch, since over 3000 U.S. residents die due to epilepsy every year.



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Tetra Pak announces target to reach net-zero GHG emissions by 2030
Tetra Pak announces target to reach net-zero GHG emissions by 2030
By Saipriya Iyer

Tetra Pak, a food processing and packaging solutions provider, has recently announced its target to reach net-zero GHG (greenhouse gas) emissions in its operations by 2030.

The targ...

DTE Energy pledges to reach net-zero emissions of GHG by 2050
DTE Energy pledges to reach net-zero emissions of GHG by 2050
By Saipriya Iyer

DTE Energy has reportedly pledged to reach the net-zero GHG (greenhouse gas) emissions by 2050. This can be ensured through various actions involving customers, suppliers, and its infrastructure, that align with the lo...

Researchers investigate a novel treatment for Childhood Alzheimer’s
Researchers investigate a novel treatment for Childhood Alzheimer’s
By Saipriya Iyer

Researchers at the Lundquist Institute have reportedly collaborated with the Cure Sanfilippo Foundation on a new clinical trial to investigate if repurposing an anti-inflammatory drug could provide relief to children t...